Table 2 Clinical characteristics of the cohort and receptor status for patients with IHC testing
Characteristic | Total (%) | With IHC testing (%) |
|---|---|---|
Overall | N = 402 | N = 30 |
Sex | ||
Female | 402 (100%) | 30 (100%) |
Male | 0 | 0 |
Age at diagnosis | ||
< 40 | 18 (4%) | 3 (10%) |
40–49 | 62 (15%) | 16 (53%) |
50–59 | 174 (43%) | 7 (23%) |
60–69 | 127 (32%) | 4 (13%) |
70+ | 21 (5%) | 0 |
BIRADS | ||
0,1,2 | 23 (6%) | 18 (60%) |
3 | 203 (50%) | 7 (23.3%) |
4,5,6 | 162 (40%) | 4 (13.3%) |
unknown | 14 (3%) | 1 (3.3%) |
Tumor stage | ||
I | 85 (21%) | 2 (7%) |
II | 122 (30%) | 12 (40%) |
III | 84 (21%) | 12 (40%) |
IV | 19 (5%) | 3 (10%) |
unknown | 92 (23%) | 1 (3%) |
Patients without IHC testing | 372 (93%) | 0 |
Patients with IHC testing | 30 (7%) | 30 (100%) |
ER testing | ||
positive | n.a. | 17 (57%) |
negative | 11 (37%) | |
unknown | 2 (7%) | |
PR testing | ||
positive | n.a. | 16 (53%) |
negative | 12 (40%) | |
unknown | 2 (7%) | |
HER2 testing | ||
positive | n.a. | 5 (17%) |
negative | 23 (77%) | |
unknown | 2 (7%) | |
Additional IHC testing | ||
Ki67, P53 | n.a. | 1 (3%) |
unknown | 29 (97%) | |
Subtype according to the Mexican Consensus [4] | ||
Luminal A | n.a. | 14 (47%) |
Luminal B | 3 (10%) | |
Basal-like/Triple negative | 9 (30%) | |
HER2 | 2 (7%) | |
not enough information to assign | 2 (7%) | |